Cargando…

Purinergic Dysfunction in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a life‐threatening disease characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, which result in an increase in afterload imposed onto the right ventricle, leading to right heart failure. Current therapies are incapable of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Zongye, Tu, Ly, Guignabert, Christophe, Merkus, Daphne, Zhou, Zhichao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Contemporary Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727004/ https://www.ncbi.nlm.nih.gov/pubmed/32867554 http://dx.doi.org/10.1161/JAHA.120.017404

Ejemplares similares

Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension
por: Cai, Zongye, et al.
Publicado: (2020)

The Role of Regulatory T Cells in Pulmonary Arterial Hypertension
por: Qiu, Haihua, et al.
Publicado: (2019)

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
por: Prins, Kurt W., et al.
Publicado: (2018)

Pulmonary Hypertension in Mitral Regurgitation
por: Patel, Harsh, et al.
Publicado: (2014)

Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα
por: Cai, Zongye, et al.
Publicado: (2022)

Biomechanical and Mechanobiological Drivers of the Transition From PostCapillary Pulmonary Hypertension to Combined Pre−/PostCapillary Pulmonary Hypertension
por: Allen, Betty J., et al.
Publicado: (2023)

Pathogenesis of pulmonary arterial hypertension: lessons from cancer
por: Guignabert, Christophe, et al.
Publicado: (2013)

Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer
por: Maron, Bradley A.
Publicado: (2023)

Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease
por: Lteif, Christelle, et al.
Publicado: (2021)

Transition from post‐capillary pulmonary hypertension to combined pre‐ and post‐capillary pulmonary hypertension in swine: a key role for endothelin
por: van Duin, Richard W. B., et al.
Publicado: (2018)

Circulating Biomarkers in Coronary Microvascular Dysfunction
por: Chakrala, Teja, et al.
Publicado: (2023)

Phenotype‐Directed Management of Hypertension in Pregnancy
por: McLaughlin, Kelsey, et al.
Publicado: (2022)

Purinergic interplay between erythrocytes and platelets in diabetes-associated vascular dysfunction
por: Zhou, Zhichao
Publicado: (2021)

Coronary Microvascular Dysfunction in HIV: A Review
por: Rethy, Leah, et al.
Publicado: (2019)

Hypertensive Disorders of Pregnancy and Future Maternal Cardiovascular Risk
por: Ying, Wendy, et al.
Publicado: (2018)

Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction
por: Karmouty-Quintana, Harry, et al.
Publicado: (2018)

Cardiac remodelling in a swine model of chronic thromboembolic pulmonary hypertension: comparison of right vs. left ventricle
por: Stam, Kelly, et al.
Publicado: (2019)

US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future
por: Kovell, Lara C., et al.
Publicado: (2015)

Management of Left Main Coronary Artery Disease
por: Ramadan, Ronnie, et al.
Publicado: (2018)

Physical Activity in the Prevention and Treatment of Coronary Artery Disease
por: Winzer, Ephraim Bernhard, et al.
Publicado: (2018)

Insights Into Aortic Sclerosis and Its Relationship With Coronary Artery Disease
por: Milin, Alexandra C., et al.
Publicado: (2014)

Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?
por: Herscovici, Romana, et al.
Publicado: (2018)

Off‐Pump Coronary Artery Bypass Grafting: 30 Years of Debate
por: Gaudino, Mario, et al.
Publicado: (2018)

Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease
por: Wang, Juan, et al.
Publicado: (2019)

Altered purinergic signaling in uridine adenosine tetraphosphate-induced coronary relaxation in swine with metabolic derangement
por: Zhou, Zhichao, et al.
Publicado: (2017)

Dendritic Cells in Pulmonary Hypertension: Foot Soldiers or Hidden Enemies?
por: Guignabert, Christophe
Publicado: (2020)

Harmonizing the Paradigm With the Data in Stable Coronary Artery Disease: A Review and Viewpoint
por: Mitchell, Joshua D., et al.
Publicado: (2017)

Pulmonary hypertension associated with neurofibromatosis type 2
por: Taniguchi, Hirohisa, et al.
Publicado: (2021)

Cardiac Conduction System in Congenitally Corrected Transposition of the Great Arteries and Its Clinical Relevance
por: Baruteau, Alban‐Elouen, et al.
Publicado: (2017)

Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes
por: Gaudino, Mario, et al.
Publicado: (2019)

Therapeutic Management of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva: Current Evidence, Proposed Approach, and the Unknowing
por: Bigler, Marius Reto, et al.
Publicado: (2022)

Magnetic Resonance Imaging and Computed Tomography for the Noninvasive Assessment of Arterial Aging: A Review by the VascAgeNet COST Action
por: Bianchini, Elisabetta, et al.
Publicado: (2023)

Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension
por: Shihan, Mazen, et al.
Publicado: (2021)

The Emerging Role of Irisin in Cardiovascular Diseases
por: Fu, Jinjuan, et al.
Publicado: (2021)

Changes in Cardiomyocyte Cell Cycle and Hypertrophic Growth During Fetal to Adult in Mammals
por: Bishop, Sanford P., et al.
Publicado: (2021)

Brugada Syndrome: Different Experimental Models and the Role of Human Cardiomyocytes From Induced Pluripotent Stem Cells
por: Li, Yingrui, et al.
Publicado: (2022)

Diabetes and hypertension: Pivotal involvement of purinergic signaling
por: Reichert, Karine Paula, et al.
Publicado: (2021)

The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient
por: Happé, Chris, et al.
Publicado: (2020)

An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension
por: Ryanto, Gusty R. T., et al.
Publicado: (2021)

Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension
por: Rain, Silvia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lqklrj0j2eef1vb1lqcd7qg39g